Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast. Duration of the study: 1 year after initiation of prophylaxis with Emicizumab Inclusion criteria: boys aged \> 2 years, affected with severe hemophilia A with or without inhibitors Evaluated outcomes: annual bleeding rate, days of absence from school, the need for additional facteur VIII consumption, satisfaction about the treatment and quality of life. Tools used to assess quality of life are the Ivoirian version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version 2 (CHO-KLAT) and EQ-5D The satisfaction of the parents will be assessed using the patients' global impression of change scale (PGIC).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
CHU de Yopougon
Abidjan, Côte d’Ivoire
Change in annual bleeding rate
Using the patients' logbook
Time frame: change in annual bleeding rate from baseline at 6 months and 12 months
Change in the scores of HR-QoL tools CHO-KLAT and EQ-5D in children treated with Emicizumab
Using the CHO-KLAT and EQ-5D. The scales range from 0 to 100 with 0 representing the worst quality of life and 100 the best quality of life score
Time frame: Change in the scores of HR-QoL tools CHO-KLAT and EQ-5D at 6 months.
Satisfaction of the parents about the treatment with Emicizumab after 6 month
Usign the PGIC (scale ranging from extremely satisfied to extremely unsatisfied)
Time frame: Assessment at 6 months after initiation of Emicizumab
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.